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ABSTRACT
Spliceosomes remove introns from primary gene
transcripts. They assemble de novo on each intron
through a series of steps that involve the incorpor-
ation of five snRNP particles and multiple
non-snRNP proteins. In mammals, all the intermedi-
ate complexes have been characterized on one
transcript (MINX), with the exception of the very
first, complex E. We have purified this complex by
two independent procedures using antibodies to
either U1-A or PRPF40A proteins, which are known
to associate at an early stage of assembly. We dem-
onstrate that the purified complexes are functional
in splicing using commitment assays. These
complexes contain components expected to be in
the E complex and a number of previously unrecog-
nized factors, including survival of motor neurons
(SMN) and proteins of the SMN-associated
complex. Depletion of the SMN complex proteins
from nuclear extracts inhibits formation of the E
complex and causes non-productive complexes to
accumulate. This suggests that the SMN complex
stabilizes the association of U1 and U2 snRNPs
with pre-mRNA. In addition, the antibody to
PRPF40A precipitated U2 snRNPs from nuclear
extracts, indicating that PRPF40A associates with
U2 snRNPs.
INTRODUCTION
In eukaryotes, the majority of primary gene transcripts
(pre-mRNA) undergo splicing, a process that removes
introns and joins exons to produce messenger RNA
(mRNA). Splicing is catalysed by the spliceosomes,
which contain ﬁve small ribonucleoprotein particles (U1,
U2, U4, U5, and U6 snRNPs) and many non-snRNP
proteins (1,2). The assembly of spliceosomes has been
studied in most detail on transcripts containing a
minimal functional unit (exon–intron–exon).
Spliceosomes assemble in a series of consecutive steps
that produce complexes E, A, B and C. First, in the E
complex, the 50- and 30-splice sites (SS) of an intron are
recognized by the speciﬁc binding of the U1 snRNP and
the proteins U2 auxiliary factor (U2AF), respectively.
Signiﬁcantly, the pre-mRNA substrate is committed to
the splicing pathway and the splice sites are in close prox-
imity (3,4). The complex contains the U2 snRNP particle
as a component, which is essential for its formation (5–7).
At this stage, association of the U2 snRNP with the
complex is weak but the underlying mechanism is not cur-
rently understood in detail. The next complex to form is
complex A, which requires ATP. In this complex, the U2
snRNP is bound stably by base pairing to the branchpoint
sequence, and U2-associated proteins of the SF3A/B
complexes are bound to the anchoring site upstream of
the branchpoint (8). This conformation serves as a
binding platform for the U4/U6.U5 tri-snRNP, which cul-
minates in the formation of complex B. The fully
assembled spliceosome contains all ﬁve snRNPs and
becomes competent for splicing through a series of re-
arrangements. These rearrangements result in the dissoci-
ation of U1 and U4 snRNPs and the formation of the
catalytic centre for the ﬁrst transesteriﬁcation reaction,
in which the 50-exon is displaced and the lariat intron is
formed. This produces complex C. The second transester-
iﬁcation reaction results in intron removal and the joining
of exons (1,9).
The components of complexes A, B and C have been
characterized in greatest detail on a transcript named
MINX, which is derived from adenovirus sequences
(10–19). However, the ﬁrst complex in this series, E, has
not been puriﬁed and characterized. The only E complexes
characterized in any detail were assembled on substrates
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containing a neuron-speciﬁc exon, the N1 exon of c-src
pre-mRNA (20,21). The protein composition of
complexes formed on these transcripts provided important
insights into the mechanism by which the exon is re-
pressed, but it is not clear whether these complexes ﬁt
into the constitutive assembly pathway deﬁned by
MINX. For example, it is not clear whether the process
of assembling complex A involves the same steps for c-src
in WERI extracts as for MINX in HeLa. The progression
from E complex to A complex can be understood only by
determining the composition of both complexes on a
common pre-mRNA. For this reason, we have puriﬁed
and characterized complex E formed on MINX RNA in
HeLa nuclear extracts.
The E complex we puriﬁed contains some factors in
common with the A complex. In addition, we identiﬁed
novel components that are speciﬁc for the E complex.
These include the proteins of the survival of motor
neurons (SMN) complex. Our data suggest that the
SMN complex proteins are required for stabilizing the
interactions between U1 and U2 snRNP with
pre-mRNA in the E complex. Moreover, using a
PRPF40A-speciﬁc antibody, we puriﬁed U2 snRNP
complexes that contained PRPF40A and the SWI/SNF
chromatin remodelling complex proteins. The E complex
appears to be assembled from three principal
sub-complexes: the U1 snRNP, the U2 snRNP and the
SMN-associated complex.
MATERIALS AND METHODS
Antibodies
Rabbit polyclonal antibodies were raised (by Eurogentec)
against peptides of U1A (amino acid 1–14), PRPF40A
(amino acid 380–394), SF3A2 (amino acid 444–458) and
puriﬁed using a SulfoLink column (Pierce) containing
the antigenic peptides according to the manufacture
procedure. The antibodies to SMN1 and GEMIN3
were purchased from BD Bioscience (manufacturer
number 610647 and 612152, respectively). The antibodies
to SIP1 (MANSIP1A), GEMIN5 (GEM5M), GEMIN6
(GEM6B) and GEMIN7 (GEM7B) were kindly
provided by the MDA Monoclonal Antibody Resource
(22). The antibodies to ACTL6A [BAF53 (N-19):
sc-47808] and DDX15 [DDX15 (T-20): sc-67550 and
(C-16): sc-67547] were purchased from Santa Cruz
Biotechnology.
In vitro transcription and splicing
MINX pre-mRNA was synthesized from a PCR product
template of pMINX plasmid (23) using MEGAshortscript
kit (Ambion). [32P]-labelled MINX pre-mRNA was
synthesized from the same template as described before
(speciﬁc activity 315 000 cpm/pm) (24) and mixed with
unlabelled MINX for easier monitoring of complexes.
HeLa nuclear extract was prepared according to Dignam
et al. (25). Splicing reactions were assembled either with
the isolated E complex or an equivalent amount of naked
pre-mRNA in the presence of 33% nuclear extract, treated
or untreated with oligonucleotides/antibodies, 2.5mM
MgCl2, 2mM ATP and 10mM creatine phosphate.
Reactions were incubated at 30C for the times indicated.
RNA was extracted and analysed by 14% PAGE followed
by radiography.
Puriﬁcation of the E complex with the antibody to U1A
To assemble E complex, nuclear extract was ﬁrst dialysed
against 20mM HEPES (pH 7.9), 20% glycerol (26). A mix
(2.4ml) containing 40% nuclear extract and 65mM KCl
was depleted of endogenous ATP by incubating at 30C
for 20min and then 15 nM MINX pre-mRNA was added.
After assembly at 30C for 10min, the reaction was loaded
on six 4ml 10–50% glycerol gradients containing 20mM
HEPES (pH 7.9), 65mM KCl and centrifuged in a Sorvall
TH660 rotor at 29 000 rpm for 14 h. Gradients were
fractionated manually into 175 ml aliquots and counted
by Cherenkov. The major pre-mRNA peak, fractions
14–19, were combined and dialysed against 2 l of IP150
(20 mM HEPES, (pH 7.9), 150mM NaCl, 0.05% NP-40,
0.5mM DTT) for 3 h. For IPs, 400 ml of Protein A
Sepharose (PAS, GE Healthcare) were charged with
150 mg of an antibody to U1A and pre-blocked with
0.3mg/ml BSA and 50 mg/ml yeast tRNA. To each 30 ml
aliquot of beads 1.5ml of dialysed gradient fractions were
added and incubated with rotation at 4C for 3 h.
Following six washes with IP150, complexes were eluted
into 800 ml of the same buffer containing 0.6mg/ml anti-
genic peptide. For analysis of complexes, the eluted
material was loaded on two 4ml 10–50% glycerol gradi-
ents containing 20mM HEPES (pH 7.9), 65mM KCl and
centrifuged in a Sorvall TH660 rotor at 26 300 rpm
for 13 h.
RNA was extracted from each gradient fraction with
phenol/chloroform/isoamylalcohol (PCA, 25:24:1) and
precipitated with ethanol. RNA was separated by 10%
denaturing PAGE and visualized by silver staining. For
identiﬁcation of the protein composition by MS, corres-
ponding gradient fractions were combined, diluted
two-fold with 20mM HEPES (pH 7.9), 150mM NaCl
and complexes were pelleted in a Sorvall TH660 rotor at
60 000 rpm for 6 h. The pellet was re-suspended in the re-
maining 60 ml of solution and the proteins were reduced in
the presence of 1% SDS and 100mM DTT at 37C for
45min.
For western blotting, eluted complexes were loaded on
one 4ml 10–30% glycerol gradient and 90 ml of each
fraction were separated by 10% SDS–PAGE, transferred
to a nitrocellulose membrane and probed with antibodies.
Puriﬁcation of the E complex with the antibody to
PRPF40A
Four hundred microlitres of the pre-blocked PAS were
charged with 170 mg of afﬁnity puriﬁed antibodies. IP
was carried out from the E complex-assembly reaction
(2.4ml) diluted with 1ml of IP150 buffer as described
before. Complexes were eluted in 1.6ml of IP150 contain-
ing 0.6mg/ml antigenic peptide. The eluate was loaded on
four 4ml 10–50% glycerol gradients containing 20mM
HEPES (pH 7.9), 65mM KCl and centrifuged in a
Sorvall TH660 rotor at 27 400 rpm for 12 h. Gradient
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fractions were measured by Cherenkov counting and
RNA was analysed by denaturing PAGE. For western
blotting, 90 ml of each fraction were loaded directly on
10% SDS–PAGE and processed as described above.
Mass spectrometry of the E complex
Of each complex, 1.26 pmoles isolated with antibodies to
PRPF40A and U1A were separated by 8/14% SDS–
PAGE and stained with colloidal Coomassie G250. Each
gel lane was cut into 54 slices and an in-gel trypsin digest
was carried out. LC–MS/MS was performed upon each
sample using a 4000 Q-Trap mass spectrometer (Applied
Biosystems, Warrington, UK). Peptides resulting from
in-gel digestion were loaded at high ﬂow rate onto a
reverse-phase trapping column (0.3mm i.d. 1mm), con-
taining 5 mm C18 300 A˚ Acclaim PepMap media (Dionex,
UK) and eluted through a reverse-phase capillary column
(75 mm i.d. 150mm) containing Waters Symmetry
C18 100 A˚ media (Waters, UK) that was self-packed
using a high pressure packing device (Proxeon
Biosystems, Odense, Denmark). The output from the
column was sprayed directly into the nanospray ion
source of the 4000 Q-Trap mass spectrometer. Fragment
ion spectra generated by LC–MS/MS were searched using
the MASCOT (27) search tool against the National Center
for Biotechnology Information non-redundant protein
database using appropriate parameters: peptide mass tol-
erance=0.4 Da; fragment mass tolerance=0.6 Da; the
enzyme was selected as trypsin with one missed cleavage
site considered; carbamidomethyl (C) was selected as a
ﬁxed modiﬁcation and oxidation (M) as a variable modi-
ﬁcation. The criteria for protein identiﬁcation were based
on the manufacturer’s deﬁnitions (Matrix Science Ltd.).
Basically candidate peptides with probability-based
Mowse scores exceeding threshold (P< 0.05), and thus
indicating a signiﬁcant or extensive homology were
referred to as ‘hits’. The highest scoring fragment ion
spectrum from each protein hit was manually inspected
to ensure its validity and thus minimize potential false
positives in the data set.
Depletion of HeLa nuclear extracts
To deplete U1 and U2 snRNPs, 100 ml of nuclear extract
in 20mM HEPES (pH7.9), 65mM KCl, 2.2mM MgCl2,
0.2mM EDTA, 0.5mM PMSF, 0.1mM DTT, 20%
glycerol were incubated in the presence of 1 mg each oligo-
nucleotide against U1 and U2 snRNAs (U2-E15 and
U1-50C) and 2U of RNsae H (Promega) for 1.5 h as
described previously (28). To analyse digestion of the
targeted snRNP particles, the RNA was extracted from
10 ml aliquots and analysed by 10% PAGE followed by
silver staining. For SMN depletion, 200 ml of PAS were
charged with 40 mg of an antibody to SMN and
pre-blocked with 0.3mg/ml BSA and 50 mg/ml yeast
tRNA. Two hundred microlitres of Hela nuclear extracts
at either 200 or 700mM NaCl were treated twice with
PAS–SMN antibody-conjugate or PAS only as a
control. Ten microlitres of extract were used for western
blot analysis. The extracts were dialysed against buffer
containing 20mM HEPES (pH 7.9), 100mM KCl,
0.5mM DTT, 15% glycerol and used at concentrations
of 40% for splicing and the E complex formation.
Analysis of E complex formation in the SMN-depleted
extract by glycerol gradient centrifugation
The E complexes were assembled in a reaction containing
40% nuclear extract, 65mM KCl, 10 nM MINX. The re-
actions were diluted two-fold with chilled buffer contain-
ing 20mM HEPES (pH 7.9), 65mM KCl, loaded on the
10–50% glycerol gradient and centrifuged in TH660 rotor
at 24 500 rpm for 15 h.
Isolation of U2 snRNPs with the antibody to PRPF40A
The IP was carried out using 150 ml of pre-blocked PAS
charged with 90 mg of afﬁnity puriﬁed antibody to
PRPF40A from the reaction (300 ml) containing 40%
nuclear extract, 20mM HEPES (pH 7.9), 65mM KCl
and depleted of endogenous ATP by incubating at 30C
for 20min. IP was carried out in the IP150 buffer at 4C
for 2.5 h. The bound material was eluted in 400 ml of IP150
containing 0.6mg/ml of antigenic peptide at 4C for 1 h
and loaded on the 4ml 10–30% glycerol gradient contain-
ing 150mM NaCl. Gradients were centrifuged in a Sorvall
TH660 rotor at 24 800 rpm for 15 h. RNA from the
gradient fractions was extracted and analysed by 10%
PAGE followed by silver staining. Proteins from fractions
8–11 were precipitated with acetone, re-suspended in
SDS-loading buffer and separated by 10/13% SDS–
PAGE for MS analysis.
RESULTS
Isolation of the E complex
Spliceosomes are dynamic molecular machines that
undergo multiple rearrangements during the splicing
cycle. Their heterogeneity is a well-documented problem
for structural studies (29,30). Therefore, to purify the E
complex, we used antibodies to proteins that associate
with the spliceosome transiently (16). We selected the U1
snRNP as it is a major factor that triggers spliceosome
assembly and then dissociates from the complex before
the catalytic spliceosome is formed. We raised an
antibody to the U1 snRNP-associated protein U1A
(encoded by the SNRPA gene), for which few interacting
partners are known and the chances of being accessible to
an antibody are higher. We also targeted PRPF40A
(FBP11), a homologue of the essential yeast Prp40p
protein, which has been proposed to bridge the intron’s
splice sites. The peptide antibodies raised against these
proteins speciﬁcally recognized the corresponding poly-
peptides on western blots of the HeLa nuclear extract
and efﬁciently precipitated pre-mRNA from splicing reac-
tions (data not shown).
The E complex was assembled using MINX pre-mRNA
in HeLa nuclear extracts in the absence of ATP (5,31).
Before immunoprecipitation (IP) of complexes with the
U1A-speciﬁc antibody, the E complex-assembly reaction
was fractionated by 10–50% glycerol gradient centrifuga-
tion to separate spliceosomal complexes from free U1
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snRNP particles. The concentration of U1 snRNPs in
HeLa nuclear extracts is 200 nM, at least an order of
magnitude greater than the concentration of the
pre-mRNA (32). The position of complexes in the
gradient (fractions 14–19) was determined by monitoring
the distribution of radioactively labelled pre-mRNA by
Cherenkov counting (Figure 1a). The sedimentation
value of complexes was determined by comparison with
the 30S and 50S ribosomal subunits and corresponds to
35–40 S, which is much larger than the 10S of U1 snRNPs.
Complexes were isolated from fractions 14–19 using
U1A-speciﬁc antibody immobilized on PAS and eluted
from the column with the antigenic peptide to minimize
any unspeciﬁc background. To prove the integrity of the
isolated complexes, the eluted material was analysed again
by 10–50% glycerol gradients. The material migrated as a
single peak (Figure 1b; fractions 12–17), indicating that
the isolated complexes are stable and homogeneous. The
RNA was extracted from the gradient fractions and
analysed by denaturing PAGE followed by silver
staining (Figure 1c). Fractions 12–17 contained
pre-mRNA and stoichiometric amounts of U1 and U2
snRNAs, which are characteristic of the E complex.
Some U1 snRNPs were detected on the top of the
gradient (Figure 1c; fractions 3–6). It is possible that
some free U1 snRNPs were present in the E complex frac-
tions and were precipitated independently of the
spliceosomal complexes (33).
An alternative method for puriﬁcation of the E complex
began with direct addition of the assembly reaction to
PAS beads charged with an antibody to PRPF40A.
Complexes eluted from the beads using the antigenic
peptide were further puriﬁed by glycerol gradient centri-
fugation under the same conditions as before.
Signiﬁcantly, both puriﬁcations resulted in the isolation
of complexes with similar migration abilities (Figure 1b).
RNA analysis of the gradient fractions showed that the
isolated complexes contained pre-mRNA and U1 and U2
snRNPs (Figure 1d; fractions 12–17). In addition, a sig-
niﬁcant amount of U2 snRNA was found in fractions
Gradient Fractions
0 2 4 6 8 10 12 14 16 18 20 22 24
No
rm
al
ise
d 
Ch
er
en
ko
v
0.0
0.2
0.4
0.6
0.8
1.0 PRP40A 
U1A 
30S 50S
Gradient Fractions
0 2 4 6 8 10 12 14 16 18 20 22 24
N
or
m
al
is
ed
 C
he
re
nk
ov
0.0
0.2
0.4
0.6
0.8
1.0
1.2
(a) (c)
(b) (d)
pre-mRNA
U2
U1
U5
U4
U6
*
*
pre-mRNA
U2
U1
U5
U4
U6
*
*
1 3 5 7 9 11 13 15 17 19 21 23 24222 4 6 8 10 12 14 16 18 20M
M 1 3 5 7 9 11 13 15 17 19 21 23 24222 4 6 8 10 12 14 16 18 20
Figure 1. Isolation and characterization of the E complex. (a) The E complex was assembled on MINX pre-mRNA in HeLa nuclear extract and the
reaction was fractionated on a 10–50% glycerol gradient. The gradient fractions were counted by Cherenkov and the position of the labelled
pre-mRNA is indicated. The major peak, fractions 14–19, was used in IPs with the U1A-speciﬁc antibody. (b) Complexes isolated with the
U1A-speciﬁc antibody (grey circles) and with the PRPF40A-speciﬁc antibodies (black circles) were analysed by 10–50% glycerol gradients. Both
puriﬁcations yielded complexes with similar 35–40S values. The positions of the E. coli 50S and 30S ribosomes are indicated. (c) RNA was recovered
from the gradient fractions of the U1A-speciﬁc isolation, analysed by the 10% denaturing PAGE and visualized by silver staining. (d) The RNA
proﬁle from the gradient fractions of complexes isolated with the antibody to PRPF40A. Total RNA extracted from the nuclear extract was used as
a marker (M). The identity of RNAs is indicated on the left. The asterisks correspond to the 5S and 5.8S ribosomal RNAs.
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7–10 (Figure 1d). This peak was absent from the
U1A-associated complexes (Figure 1c) and is therefore
unlikely to have arisen from dissociation during centrifu-
gation. Indeed, we infer that these U2 snRNPs were in
distinct complexes that were also selected by the
PRPF40A-speciﬁc antibody. The relative migration of
these U2-containing complexes corresponded to 20S
(peak fractions 8–9), which is higher than the previously
characterized 17S U2 snRNPs (34,35).
PRPF40A associates with U2 snRNPs
PRPF40A was not identiﬁed as a U2-associated protein
in previous isolations of the U2 snRNPs (34,35).
Moreover, its yeast homologue, Prp40p, is a compo-
nent of the U1 snRNP and not U2 (36,37). To inves-
tigate whether there is an alternative form of U2
snRNPs present in HeLa nuclear extract, we carried
out IPs with the PRPF40A-speciﬁc antibody from re-
actions in the absence of pre-mRNA. The analysis of
an eluate by glycerol gradient centrifugation showed that
U2 particles were selected again (Figure 2a; fractions
9–11), indicating the presence of such complexes in
HeLa extract.
Next, we determined the full protein composition of the
novel PRPF40A–U2 complex. Proteins were recovered
from gradient fractions 9–11 containing U2 snRNAs,
fractionated by SDS–PAGE, and stained with
Coomassie Blue (Figure 2b). The identities of proteins
were determined after in-gel digestion with trypsin using
a Q-Trap 4000 mass spectrometer and are listed in Table 1
and Supplementary Table S1. Consistent with the presence
of the U2 snRNA, the complex contained all the
U2-speciﬁc proteins identiﬁed in previous isolations
(34,35). In addition, we identiﬁed a number of novel
components in association with the PRPF40A–U2
complex, including the SWI/SNF chromatin remodelling
complex proteins such as ARID1A/1B/2, SMARCA1/2/4,
PBRM1, SMARCB1, SMARCC1/2, SMARCD1,
SMARCE1, ACTL6A and ACTBL2. In addition to
these, we identiﬁed several transcription factors that
have been identiﬁed as spliceosomal components in
previous puriﬁcations of splicing complexes. These
include RUVBL2/1 (TIP48/TIP49), RBM25 (RED120/
S164), SART3 (TIP110), ARS2, BAT1 (UAP56),
HTATSF1 (Tat-SF1), YEATS2 and CCNK. Other tran-
scription factors produced insigniﬁcant scores, indicating
that most of these proteins are more likely to be present in
sub-stoichiometric amounts. The presence of additional
proteins correlates with the increased S-value of the
complex. The common trait shared by these proteins is
their involvement in the regulation of transcriptional
elongation by RNAP II, which is coupled to histone modi-
ﬁcation and chromatin remodelling. Therefore, our data
strongly support the hypothesis that there is
co-transcriptional recruitment of the U2 snRNP to
nascent transcripts.
The E complex is a functional stable spliceosomal
intermediate
It was important to test whether the E complex that we
isolated represents a functional spliceosomal intermediate.
For this purpose, we treated an extract with RNase H in
the presence of oligonucleotides complementary to U1
and U2 snRNAs (28). The U1 and U2 snRNPs were
digested (Figure 3a), leading to a reduction in splicing
activity. Then, we tested whether the isolated E complex
would support splicing of the substrate pre-mRNA in this
extract. Splicing in the E complex was unaffected by the
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Figure 2. Characterization of the PRPF40A–U2 snRNP complex. (a) The PRPF40A-speciﬁc antibodies precipitate U2 snRNPs from HeLa nuclear
extract. The IPs were carried out from reactions containing pre-mRNA (left) or without pre-mRNA (right). Eluates from both IPs were fractionated
by 10–30% glycerol gradients. RNA from the odd fractions was analysed by the 10% denaturing PAGE and visualized by silver staining.
The identity of the RNAs is indicated on the left. (b) Identiﬁcation of U2 snRNP-associated proteins. Proteins from the peak fractions of the
U2 snRNP gradient (fractions 9–11) were recovered, fractionated by SDS–PAGE on the 10/13% polyacrylamide gel and stained with Coomassie
Blue. The identity of proteins was determined by MS.
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Table 1. Proteins of the E complex and novel U2 snRNPs
Gene name Mol Mass E complex Ab to PRPF40A E complex Ab to U1A U2 snRNP Ab to PRPF40A
pept emPAI pept emPAI pept emPAI
Sm proteins
SNRPB 24 765 5 0.33 6 0.77 6 N/A
SNRPD1 13 273 1 N/A 1 0.3 2 N/A
SNRPD2 13 632 9 4.87 11 6.56
SNRPD3 14 021 2 0.64 5 0.64 1 N/A
SNRPE 10 854 2 0.87 2 0.87 1 N/A
SNRNPF 9 776 1 N/A 5 N/A
SNRPG 8547 3 N/A
U1 snRNP
SNRP70 51 583 4 0.32 12 0.52
SNRPA 31 259 4 0.41 7 0.77 1 N/A
SNRPC 17 552 3 3 0.82
U2 snRNP
SNRPA1 28 512 7 1.11 6 1.11 11 N/A
SNRNPB2 25 470 4 0.75 3 0.52 5 N/A
SF3A1 88 888 19 0.92 38 2.13 40 2.4
SF3A2 49 338 8 0.44 10 0.67 8 0.44
SF3A3 59 154 22 0.73 15 1.08 20 1.65
SF3B1 146 464 55 1.39 45 1.06 58 1.84
SF3B2 97 710 29 1.18 15 0.4 33 1.35
SF3B3 136 575 23 0.62 25 0.62 31 0.9
SF3B4 44 414 2 0.18 2 0.08 3 0.27
SF3B14 14 690 8 3.13 8 3.13 6 N/A
PHF5A 13 138 1 N/A 2 N/A
U2 related
PRP40A 109 022 9 0.26 9 0.31 5 0.14
PAF60 60 009 13 0.94 29 2.99 3 0.06
DDX46 117 803 17 0.59 5 0.17
DHX15 91 673 11 0.49 1 30 1.21
SR140 118 675 2 0.03 13 0.24
CHERP 104 078 14 0.47
U4/U6.U5 tri-snRNP
PRPF8 274 738 52 0.7 2 0.03
SNRNP200 246 006 36 0.54 3 0.03
EFTUD2 110 336 13 0.48 8 0.22 4 0.07
PRPF6 107 656 8 0.27 1 0.03
DDX23 95 866 2 0.04 2 0.08
PRPF3 77 652 14 0.52
PRPF31 55 649 4 0.21
PRPF4 59 097 4 0.28 2 0.06
PPIH 19 481 4 N/A
LSM4 15 511 1 0.25
SART1 90 371 2 0.08
USP39 65 739 2 0.12
SNRNP40 39 742 1 N/A
SMN associated
SMN1 32 285 1 0.12 1 0.12
SIP1 32 021 2 0.25
DDX20 92 981 3 0.08 3 0.08
GEMIN4 121 681 9 0.27 23 0.57
GEMIN5 170 793 2 0.04 9 0.21
GEMIN6 18 983 1 0.2 3 0.74
GEMIN8 28 904 1 0.13
STRAP 38 756 6 0.32
Splicing related
NCBP1 92 864 24 1.36 32 1.65
NCBP2 18 161 1 0.21 4 0.21
U2AF1 28 368 4 0.46 2 0.21
U2AF2 53 809 14 1.39 7 0.49
SF1 8 0.45
SRRM2 300 179 8 0.08 7 0.06
SFRS1 27 842 10 1.78 7 0.89 1 N/A
SFRS2 25 461 2 0.32
SFRS2B 32 382 3 0.25 1 0.12
SFRS3 19 546 2 0.43
SFRS4 56 759 2 0.07
SFRS5 31 359 5 0.57
SFRS6 39 677 2 0.2 3 0.31
SFRS7 27 578 4 0.29 5 0.68
SFRS8 105 190 1 0.04
SFRS11 53 624 2 0.07
SFRS12 59 402 2 0.06
SFRS15 126 132 2 0.03
(continued)
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Table 1. Continued
Gene name Mol Mass E complex Ab to PRPF40A E complex Ab to U1A U2 snRNP Ab to PRPF40A
pept emPAI pept emPAI pept emPAI
HNRNPA0 30 993 2 0.26
HNRPA1L3 34 373 2 0.11 2 0.23 2 N/A
HNRNPA2B1 37 464 1 0.1 1 0.1 6 N/A
HNRNPC 33 707 1 0.11 2 0.24
HNRNPD 38 581 1 0.1
HNRNPF 45 985 2 0.08
HNRNPH1 49 484 1 0.08
HNRNPK 51 230 1 0.07
HNRNPL 64 720 2 0.12
HNRNPM 77749 6 0.2
SYNCRIP 69 788 14 0.59 3 0.11 6 0.23
HNRNPR 71 184 6 0.16 8 0.36 1 0.05
HNRNPU 91 198 4 0.13 3 0.08 7 0.13
RBM7 30 485 1 0.12 3 0.42
RBM10 103 811 3 0.07
RBM17 45 162 1 0.08 8 0.75
RBM25 94 407 34 1.42 12 0.31 8 0.21
RBM39 59 628 7 0.35 6 0.27
RBM42 50 496 1 0.07
RBMXL2 42 929 4 0.29
ARS2 101 060 18 0.65 9 0.24 7 0.11
LUC7L3 (CROP) 51 834 6 0.42 4 0.32
LUC7L2 46 942 3 0.08
PCBP1 37 987 2 0.21 3 0.33
PCBP2 38 955 3 0.32
SKIV2L2 118 756 5 0.13 3 0.1 3 0.1
KHSRP 73 443 2 0.1
FUS 53 622 2 0.14
DDX5 69 618 3 0.17 6 0.37
DDX17 72 953 3 0.1 2 0.05
DHX9 142 181 4 0.05
DDX39 49 611 1
PRPF19 55 603 7 0.57 3 0.21
SART3 110 721 3 0.1 6 0.18
BCAS2 26 229 1 0.15
ZCCHC8 79 156 1 0.05
DNAJC8 29 823 4 N/A
THOC4 26 872 1 0.14
BAT1 49 416 1 0.08 4 0.16
YBX1 35 903 1 0.1
RUVBL2 51 296 2 0.15 2 0.15 14 1.02
RUVBL1 50 538 6 0.53
CPSF1 162 036 1 0.02
NUDT21 26 268 2 0.14
CPSF6 59 344 1 0.06 7 0.28
CPSF7 52 189 1 0.07
HTATSF1 86 371 13 0.46 6 0.18 28 1.52
Chromatin remodeling
ARID1A 242 805 5 0.03
ARID1B 237 057 17 0.22
ARID2 198 921 10 0.18 14 0.25
SMARCA1 123 211 1 0.03
SMARCA2 181 794 15 0.22
SMARCA4 185 100 27 0.48 5 0.06 25 0.45
PBRM1 194 080 39 0.76 8 0.08
SMARCC2 133 196 25 0.73 21 0.43
SMARCC1 123 303 3 0.09 10 0.27
SMARCD1 55 195 2 0.14 11 0.8
SMARCE1 46 678 5 0.26 9 0.59
ACTL6A 47 944 6 0.46 3 0.25 8 0.57
SMARCB1 44 398 2 0.18 6 0.38
ACTBL2 42 318 2 0.09
CHD4 219 393 20 0.26
CHD8 263 977 3 0.03 30 0.39
The E complex was assembled on MINX pre-mRNA in HeLa nuclear extract and puriﬁed using either U1A- or PRPF40A-speciﬁc antibodies. In
addition, the antibody to PRPF40A precipitated novel U2 snRNPs. Proteins from puriﬁed complexes were fractionated by SDS–PAGE and sub-
jected to MS analysis. The presence of a protein in a complex is shown by the number of unique peptides and the emPAI factor (60)—where
available (note: N/A stands for not available). Calculated molecular masses for proteins and their corresponding gene names are taken from the
UniProt database. Proteins are grouped according to their known function. Additional proteins identiﬁed in puriﬁcations which are not common
components for all complexes are presented in the Supplementary Table S1.
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depletion of U1 and U2 snRNPs (Figure 3b; panels A and
B). This supports the view that the E complex we isolate is
splicing competent and does not require the association of
either U1 or U2 snRNPs, which indicates the integrity of
the complexes. Notably, the E complex generated even
more spliced product than naked pre-mRNA added to
intact mock-treated extract (Figure 3b, panels C and D).
This shows that pre-mRNA was protected from degrad-
ation in the E complex as compared to the naked
pre-mRNA. On the other hand, the E complex had no
kinetic advantage in the course of reaction, suggesting
that later steps are limiting.
The protein composition of the E complex
The proteins in the E complex must be responsible for the
initial steps in spliceosome formation and the pairing of
splice sites. Having proved that the isolated E complexes
represent a functional intermediate step in the spliceosome
assembly pathway, we analysed their composition. Equal
amounts of complexes puriﬁed by the PRPF40A- or
U1A-speciﬁc antibodies were fractionated by SDS–
PAGE and stained with Coomassie Blue (Figure 4a).
Proteins identiﬁed by MS analysis are listed in Table 1
and Supplementary Table S1.
The comparison of protein compositions revealed that
almost all proteins identiﬁed in the complex puriﬁed with
the U1A-speciﬁc antibody were present in the complex
isolated with the antibody to PRPF40A. Overall, more
proteins were identiﬁed in the preparation with the
PRPF40A-speciﬁc antibody and some common proteins
were detected by a larger number of peptides. These ob-
servations are consistent with the fact that the puriﬁcation
procedure used to isolate complexes with the antibody to
U1A was more rigorous and included fractionation of the
complexes by glycerol gradient prior to afﬁnity puriﬁca-
tion. This could result in the loss of more weakly
associated proteins. For example, the U4/U6.U5
tri-snRNP proteins were better represented in the
PRPF40A preparation, indicating the intrinsic afﬁnity of
the tri-snRNP particle for the pre-spliceosome, but at this
stage of assembly this interaction is unlikely to be stable
enough to withstand the conditions used for U1A isola-
tion. Therefore, we believe that most of the common
proteins in both isolations represent the more tightly
bound components of the E complex.
Consistent with its RNA composition, the E complex
contained U1 and U2 snRNP-associated proteins. Most of
them were identiﬁed by a similar number of peptides in
both preparations, conﬁrming that equal amounts of
complexes were subjected to the analysis. The E complex
also contained proteins that associate with pre-mRNA
directly. These include the cap-binding complex proteins
and hnRNP proteins A1, A2/B1, C, Q, R and U together
with poly(rC)-binding protein (PCBP1), SR proteins
(SFRS1, 2B, 6, 7), RNA-binding motif proteins
(RBM25, 39, 7), PUF60 and SR-related protein SRRM2
(SRp300) and CROP (Luc7A). The DEAD box family
ATP-dependent RNA helicases DDX5 (p68) and
DDX46 (hPRP5) were identiﬁed in both preparations.
In addition, proteins that affect alternative splicing and
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therefore might inﬂuence spliceosome assembly were
found in association with the E complexes. All these
proteins were also identiﬁed as components of E
complexes assembled on c-src pre-mRNA (20,21). Their
presence on both MINX and the neuron-speciﬁc substrate
suggests that they have constitutive functions in splicing.
One difference between the complexes puriﬁed by the
antibodies to PRPF40A and U1A is that the former
lacked the proteins SF1 and DDX17 (p72). This did not
prevent the complex functioning in a commitment assay
(Figure 3b).
Signiﬁcantly, the puriﬁed E complexes contain proteins
of the SMN-associated complex. Although an indirect role
for SMN in splicing has been suggested previously
(39–43), this is the ﬁrst time that the SMN complex has
been identiﬁed as a possible spliceosomal component. The
complex comprises nine proteins: SMN, GEMINS2-8 and
STRAP (UNR-IP) (44–49). We identiﬁed all of them
except GEMIN7, although GEMIN2 (SIP1) and
GEMIN8 were detected only in the PRPF40A-speciﬁc
preparation. Thus, it is likely that all proteins of the
SMN complex co-purify with the E complex.
Signiﬁcantly, neither antibody, to U1A or PRPF40A,
precipitated U1 or U2 snRNPs in association with the
SMN complex. This is consistent with the idea that the
presence of the SMN complex in the spliceosomal complex
E is independent of snRNPs. To verify the MS data, the E
complex preparations were analysed by western blotting.
Complexes were puriﬁed as previously described and
analysed by 10–30% glycerol gradients (Figure 4b and
d). Antibodies against proteins SMN (SMN1), GEMIN2
(SIP1) and GEMIN6-7 were used for detecting proteins of
the SMN complex across the entire gradients. The
designated proteins were detected in fractions correspond-
ing to the E complex with material puriﬁed via both U1A
and PRPF40A antibodies (Figure 4c and e). This provides
a strong evidence for the SMN complex proteins as com-
ponents of the E complex.
Interestingly, analysis of the complexes puriﬁed with the
antibody to PRPF40A showed two peaks for SMN (frac-
tions 11, 12 and 14–16). The major peak (fractions 14–16)
corresponds to the E complex, whereas fractions 11 and 12
do not coincide with any RNA species. It suggests that the
antibody to PRPF40A also precipitated an SMN-
containing complex in addition to the E complex and
U2 snRNP. We infer that PRPF40A–SMN complexes
might exist in HeLa nuclear extracts.
In addition, we tested some of the proteins identiﬁed in
the PRPF40A–U2 snRNP complex (Figure 4e). The signal
produced by an antibody against the U2 snRNP-speciﬁc
protein SF3A2 corresponds to the distribution of U2
snRNA across the gradient. We also used an antibody
to one of the SWI/SNF complex proteins, ACTL6A,
and detected it in the PRPF40A–U2 snRNP complex.
Depletion of the SMN protein
To test whether SMN plays a role in the formation of the
E complex, it was depleted from HeLa nuclear extract
using an antibody to SMN. Depletion was done at two
different salt concentrations, 200 and 700mM NaCl.
Depletion at the higher salt concentration resulted in
more efﬁcient removal of the proteins associated with
SMN and their presence was detected in the eluate from
the beads. Importantly, neither U1A nor SF3A proteins
were affected, indicating that the SMN complex was
removed without the U1 or U2 snRNPs (Figure 5a).
Depletion inactivated the extract (Figure 5b).
The ability of the SMN-depleted extract to form
complexes was analysed by glycerol gradient centrifuga-
tion. The reactions were loaded on the gradient and the
distribution of pre-mRNA across the gradients was moni-
tored by Cherenkov counting. The comparison of
pre-mRNA distributions displayed a striking difference
between the two extracts (Figure 5c). In the mock-depleted
extract, the major peak had the expected 35–40S value and
formation of the E complex was unaffected. In contrast,
complexes formed in the SMN-depleted extract produced
a much smaller peak corresponding to the E complex
(fractions 11–13) and the majority of pre-mRNA was
found in slower-migrating fractions (7–9) (Figure 5c). To
analyse complex formation in more detail, RNA was ex-
tracted from gradient fractions, separated by denaturing
PAGE and visualized by silver staining (Figure 5d and e).
In addition to the reduced amount of E complex, the dis-
tribution of U2 snRNA was signiﬁcantly different in the
SMN-depleted extract. The majority of the U2 snRNA
was found in fractions 4–6, not associated with the
pre-mRNA. This suggests that association of U2 snRNP
in the E complex might require SMN and its associated
proteins.
DISCUSSION
The E complex represents the ﬁrst deﬁnite complex in the
spliceosome assembly process. Previous studies identiﬁed
some of its components but a full characterization of
complex E on a standard substrate had not been done.
Here, our objective was to isolate the E complex and char-
acterize its components in detail. We carried out two in-
dependent immunopuriﬁcations with antibodies to U1A
and PRPF40A and identiﬁed their protein composition
using MS. A comparison of the isolates shows that most
proteins are common to both puriﬁcations and therefore
are likely to represent true components of the E complex.
In addition to the known factors, we have identiﬁed
several novel components. One of these is the SMN
complex, which we show might be required for
assembly. Analysis of the complexes formed in the
SMN-depleted extracts showed that U2 snRNP is no
longer associated with pre-mRNA. Since U2 snRNP is
essential for the E complex formation, our data suggest
that the SMN complex plays a role in U2 snRNP inter-
action within the complex. To conﬁrm this it would be
necessary to reconstitute the depleted extract with the
SMN complex. However, reconstitution is not yet
possible because recombinant proteins of the SMN
complex are insoluble. For this reason, we cannot estab-
lish whether the entire SMN complex is necessary for
spliceosome assembly.
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(continued)
At present the interactions between U2 snRNPs and
other factors in the E complex are poorly characterized.
Much is known about its interactions in the A complex
where, upon conformational changes induced by ATP hy-
drolysis, the U2 snRNA becomes base paired to the
branchpoint sequence and the U2-associated proteins of
the SF3A/B complex form an anchoring site on the
pre-mRNA. These rearrangements result in stable associ-
ation of U2 snRNPs in the A complex. The SMN complex
is not a component of the A complex and presumably
dissociated during the transition. It will be of interest to
elucidate the precise interactions of SMN in the E complex
in greater detail.
Deﬁciency in the SMN protein causes spinal muscular
atrophy (SMA). SMN and its associated proteins play a
major role in snRNP biogenesis, and a recent study of an
SMA mouse model detected widespread alterations in the
stoichiometry of snRNAs in different tissues (43). The
splicing of speciﬁc pre-mRNAs was inhibited in the
SMA mice, but it was not established whether this arose
from the changes in snRNP stoichiometry (43). Similar
ﬁndings were reported for S. pombe when the expression
of SMN was downregulated (39). The possible role of
SMN in spliceosome formation may explain such defects
in pre-mRNA processing observed in SMN-deﬁcient cells.
Along with the E complex, a novel U2 snRNP-
containing complex was selected by the antibody to
PRPF40A from HeLa extract. These particles have a sedi-
mentation coefﬁcient of 20S. The earliest puriﬁcation
procedure for human U2 snRNPs involved several chro-
matographic steps and resulted in isolation of 12S and 17S
U2 snRNPs, which contain only the most stably bound
components. A more recent procedure used an antibody
to SF3A2, raised against a peptide (amino acid 444–458).
In this case a number of additional proteins were identiﬁed
as components of U2, including DDX46 (PRP5), but not
PRPF40A (35). The antibody to SF3A2 was raised against
a peptide (amino acid 444–458) located in a proline-rich
region of the protein that forms the interface with
PRPF40A (56). Thus, it is possible that the use of this
epitope in SF3A2 selects against co-puriﬁcation with
PRPF40A.
The major difference between the new and previously
described U2 snRNPs is the association of the SWI/SNF
complex proteins with the particles. The SWI/SNF
complex interacts with chromatin (50), suggesting a
model in which it might serve as an adaptor for U2
snRNP association with chromatin. The same SWI/SNF
proteins were identiﬁed as components of the E complex
in this study. Their recruitment into the spliceosome is
likely to occur in a complex with the U2 snRNP.
Interestingly, the BRM protein, a component of the
SWI/SNF complex, was previously shown to associate
with nascent transcripts and affect alternative splicing
(51). This suggests that the SWI/SNF complex might be
involved in differential recruitment of the U2 snRNP to
nascent transcripts.
One of the most conspicuous features of the E complex
is the proximity between the 50- and 30-SS and the branch
sequence (3,52). Therefore, the identiﬁcation of factors
responsible for attaining this conformation is important
for understanding E complex formation. PRPF40A has
been proposed to mediate interactions between the 50-SS
and branch sequence (53). In S. cerevisiae, Prp40p is a
component of the U1 snRNP (36,37,54) and interacts
with branchpoint binding protein Msl5 (53). The human
homologue of Prp40p, PRPF40A, has also been shown to
interact with SF1, a homologue of Msl5 (53,55,56,57).
Here, we identiﬁed PRPF40A as a component of the U2
snRNPs, but its interacting partners at the 50-SS are cur-
rently unknown. It is possible that the use of peptide
antibodies prevented the recovery of U1-PRPF40A
complexes. Another proposed candidate for the bridging
of SSs is a DEAD box family ATP-dependent RNA
helicase, DDX46 (PRP5), which has been proposed to
bridge the U1 and U2 snRNPs in the A complex (58).
We identiﬁed DDX46 in the E complex, where it might
also be involved in bridging interactions. Alternatively,
SR proteins have been proposed to link the U1 snRNP
bound at the 50-SS with U2AF bound at the 30-SS (59).
Thus, it is plausible that many interactions between com-
ponents of the E complex contribute to the link between
the ends of the intron. The least understood are the inter-
actions of the U2 snRNP in the E complex. Base pairing
between the U2 snRNA and pre-mRNA has not been
detected in the E complex and moreover, its association
does not require a branchpoint sequence (5). Therefore,
elucidating the interactions of SMN-associated proteins in
the E complex might reveal the means by which U2
snRNPs associated with the complex.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Table S1 and Supplementary
Reference [60].
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